TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8306739

Group type: EXPERIMENTAL
Intervention: Artificial lung‐expanding compound (ALEC, 3.2 g via bronchoscope)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 16
Study: 2451135

Group type: EXPERIMENTAL
Intervention: Radiotherapy with concomitant bleomycin (RT-BLM)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 199
Study: 29624543

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 45
Study: 28290093

Group type: EXPERIMENTAL
Intervention: rLH supplementation with rFSH
Number of subjects: 0

Group type: COMPARATOR
Intervention: rFSH only (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 26153496

Group type: EXPERIMENTAL
Intervention: Erlotinib plus tivantinib
Number of subjects: 307

Group type: COMPARATOR
Intervention: Erlotinib plus placebo
Number of subjects: 307
Study: 23290818

Group type: EXPERIMENTAL
Intervention: Dementia
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Non-cognitive psychiatric disorders
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Staff recognition of persistent dementias
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Treatment for persistent dementia cases
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Treatment for persistent non-cognitive psychiatric disorder cases
Number of subjects: 200
Study: 21686215

Group type: EXPERIMENTAL
Intervention: Intensive dialysis (6 days/nights of dialysis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional dialysis
Number of subjects: 0
Study: 19774773

Group type: EXPERIMENTAL
Intervention: Mouthpiece
Number of subjects: 10

Group type: COMPARATOR
Intervention: No mouthpiece (Control)
Number of subjects: 10
Study: 16728295

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (4-week duration)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 30
Study: 14729296

Group type: EXPERIMENTAL
Intervention: Diabetes patient education interventions
Number of subjects: 2439

Group type: EXPERIMENTAL
Intervention: Face-to-face delivery, cognitive reframing teaching method, and exercise content
Number of subjects: 2439
Study: 11513780

Group type: EXPERIMENTAL
Intervention: Group A (intervention): excised 3 x 2 cm gastric crescent from the anterior wall of the gastric tube before constructing the cervical esophagogastric anastomosis.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group B (control): no intervention.
Number of subjects: 100
Study: 9068434

Group type: EXPERIMENTAL
Intervention: Homoeopathic arnica C30
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 8262872

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin (500 + 500 mg qds)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Aztreonam (600 tds) and Clindamycin (1000 mg tds)
Number of subjects: 104
Study: 4037642

Group type: EXPERIMENTAL
Intervention: Caudal morphine 10 mg in saline 25 ml injected into the caudal epidural space at the end of surgery
Number of subjects: 33

Group type: COMPARATOR
Intervention: Intramuscular morphine 10 mg on request in the postoperative period
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Caudal morphine 10 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Intramuscular morphine 10 mg
Number of subjects: 33
Study: 30673030

Group type: EXPERIMENTAL
Intervention: Needleless jet injection system
Number of subjects: 41

Group type: COMPARATOR
Intervention: Carpule syringe
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Traditional method of anesthesia
Number of subjects: 41
Study: 28992580

Group type: EXPERIMENTAL
Intervention: Immediate access to Ray's Night Out app
Number of subjects: 197

Group type: COMPARATOR
Intervention: Delayed access to Ray's Night Out app
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Both groups (Immediate and Delayed access)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Ray's Night Out app
Number of subjects: 197
Study: 27276234

Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure target of 110 to 139 mm Hg)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard treatment (systolic blood pressure target of 140 to 179 mm Hg)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 1000
Study: 24616593

Group type: EXPERIMENTAL
Intervention: Erythropoietin (n=20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (n=19)
Number of subjects: 39
Study: 22753922

Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg plus carboplatin/paclitaxel
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel alone (placebo)
Number of subjects: 1090
Study: 20003585

Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil 5 percent cream, three successive applications with two-week intervals
Number of subjects: 60

Group type: COMPARATOR
Intervention: Local petroleum jelly cream packing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil 5 percent cream
Number of subjects: 60
Study: 17068214

Group type: EXPERIMENTAL
Intervention: Caffeine capsules (dose = 4 mg/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Gelatin (placebo)
Number of subjects: 14
Study: 15856068

Group type: EXPERIMENTAL
Intervention: Nonfat with phytosterols (NFPS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-fat with phytosterols (LFPS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonfat placebo (NF control)
Number of subjects: 15
Study: 12469007

Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9595967

Group type: EXPERIMENTAL
Intervention: Metrifonate (100 to 180 mg loading dose for 2 weeks, followed by 30 to 60 mg maintenance dose for 24 weeks)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Metrifonate
Number of subjects: 408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study: 8572867

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment for 3 months
Number of subjects: 6530

Group type: EXPERIMENTAL
Intervention: Different methods to define a responder
Number of subjects: 6530

Group type: EXPERIMENTAL
Intervention: Placebo effect and regression to the mean
Number of subjects: 6530

Group type: EXPERIMENTAL
Intervention: Increased BP level for inclusion
Number of subjects: 6530

Group type: EXPERIMENTAL
Intervention: Oldham's method for adjusting for regression to the mean
Number of subjects: 6530
Study: 2705806

Group type: EXPERIMENTAL
Intervention: Oral iron (n = 17)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 38
Study: 322009

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 31237722

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of pelvic floor muscle contraction using 2D levator hiatal AP diameter
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of pelvic floor muscle contraction using 3D levator hiatal AP diameter
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of pelvic floor muscle contraction using hiatal area
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Correlation between ultrasound measurements and MOS score
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Ultrasound contraction scale
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Major levator injury assessment using tomographic ultrasound
Number of subjects: 195
Study: 29032175

Group type: EXPERIMENTAL
Intervention: Raloxifene 60mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Raloxifene 120mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 27120294

Group type: EXPERIMENTAL
Intervention: Subsymptom exacerbation aerobic training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Full-body stretching program
Number of subjects: 30
Study: 25534375

Group type: EXPERIMENTAL
Intervention: Anthracycline-plus-taxane combination with carboplatin (PMCb)
Number of subjects: 580

Group type: COMPARATOR
Intervention: Anthracycline-plus-taxane combination (PM)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Increased levels of stromal TILs
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: mRNA expression of immune markers (12 immune mRNA markers)
Number of subjects: 580
Study: 23592767

Group type: EXPERIMENTAL
Intervention: Radiologists with higher false-positive rates (FPRs) (FPR > 27.1%)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Radiologists with lower false-positive rates (FPRs) (FPR ≤ 27.1%)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Overall mean FPR for radiologists
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pairs of radiologists within the same screening center
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pairs of radiologists across all centers
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Academic centers
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Nonacademic centers
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Centers inside the U.S. 'histoplasmosis belt'
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Centers outside the U.S. 'histoplasmosis belt'
Number of subjects: 112
Study: 21878677

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (0.625 mg/d) plus medroxyprogesterone acetate (2.5 mg/d)
Number of subjects: 27447

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen alone
Number of subjects: 27447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27447
Study: 19190070

Group type: EXPERIMENTAL
Intervention: Breakfast providing 125 microg folate (breakfast group; n = 17)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 5 slices of whole‐meal bread providing 70 microg folate (bread group; n = 17)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Apple juice (control group; n = 17)
Number of subjects: 51
Study: 17097811

Group type: EXPERIMENTAL
Intervention: 1mg alprazolam
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 15504189

Group type: EXPERIMENTAL
Intervention: Betamethasone 8 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ondansetron 8 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline 2 ml (placebo)
Number of subjects: 10
Study: 11072160

Group type: EXPERIMENTAL
Intervention: Amifostine during radiation therapy (RT)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control group (non-amifostine treated patients)
Number of subjects: 303
Study: 9255079

Group type: EXPERIMENTAL
Intervention: Ampicillin and metronidazole
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 8438744

Group type: COMPARATOR
Intervention: Atenolol (n = 71)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Doxazosin (n = 51)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Atenolol (n = 23)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Doxazosin (n = 18)
Number of subjects: 191
Study: 3324039

Group type: EXPERIMENTAL
Intervention: Intralesional steroid injection (2.5 mg) and griseofulvin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Griseofulvin only
Number of subjects: 30
Study: 30945920

Group type: EXPERIMENTAL
Intervention: Transitional Work (TW)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Nonengagers (Control)
Number of subjects: 270
Study: 29589786

Group type: EXPERIMENTAL
Intervention: Exeter polished tapered stem and Unitrax modular head
Number of subjects: 964

Group type: COMPARATOR
Intervention: Thompson hemiarthroplasty
Number of subjects: 964
Study: 26839075

Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum R0071
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum ssp. infantis R0033
Number of subjects: 581

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 581
Study: 24804698

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 64942

Group type: COMPARATOR
Intervention: No diabetes (Control)
Number of subjects: 64942
Study: 22840687

Group type: EXPERIMENTAL
Intervention: Self-reported assessment of care from any healthcare source (CDM clinic or elsewhere)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported measure of care at a CDM clinic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visit frequency based measure
Number of subjects: 0
Study: 19822721

Group type: EXPERIMENTAL
Intervention: BLETRAC (Bilateral Leg Training with Rhythmic Auditory Cueing)
Number of subjects: 24

Group type: COMPARATOR
Intervention: BATRAC (Bilateral Arm Training with Rhythmic Auditory Cueing)
Number of subjects: 24
Study: 18020847

Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 121
Study: 15316334

Group type: EXPERIMENTAL
Intervention: peg-IFN alpha-2a 180 microg once weekly plus ribavirin 400 mg twice daily
Number of subjects: 859

Group type: COMPARATOR
Intervention: IFN alpha-2a 3 million units three times weekly plus ribavirin 400 mg twice daily
Number of subjects: 859
Study: 11254919

Group type: EXPERIMENTAL
Intervention: TRANS-diet (partially hydrogenated soybean oil)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: PUFA-diet (high in polyunsaturated fatty acids)
Number of subjects: 9

Group type: COMPARATOR
Intervention: PALM-diet (palm oil)
Number of subjects: 9
Study: 8996463

Group type: EXPERIMENTAL
Intervention: Fully adherent exercise group
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Partially adherent exercise group
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 8287661

Group type: EXPERIMENTAL
Intervention: Cardiac transplant group
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study: 3305990

Group type: EXPERIMENTAL
Intervention: Fine needle aspiration of the prostate before prostatectomy
Number of subjects: 102
Study: 31756173

Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy (MIDP)
Number of subjects: 2921

Group type: COMPARATOR
Intervention: Open distal pancreatectomy (ODP)
Number of subjects: 2921
Study: 30411130

Group type: EXPERIMENTAL
Intervention: Nd:Yap laser combined with composite resin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 70
Study: 26759152

Group type: EXPERIMENTAL
Intervention: Higher age (73.3%)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Severe pain (64.0%)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Severe radiological OA (96.9%)
Number of subjects: 326
Study: 24977974

Group type: EXPERIMENTAL
Intervention: Hormonal contraception
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 22999700

Group type: EXPERIMENTAL
Intervention: Shang Ring circumcision
Number of subjects: 833

Group type: COMPARATOR
Intervention: Conventional sleeve resection circumcision
Number of subjects: 833
Study: 20435202

Group type: EXPERIMENTAL
Intervention: Core laboratory (CL) estimation of post-PCI TIMI flow grade
Number of subjects: 922

Group type: COMPARATOR
Intervention: Local investigators (LI) estimation of TIMI flow grade
Number of subjects: 922

Group type: COMPARATOR
Intervention: Pre-PCI TIMI flow grade assessment
Number of subjects: 922
Study: 18664620

Group type: EXPERIMENTAL
Intervention: Single oral doses of pantoprazole (20 mg or 40 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single intravenous doses of pantoprazole (0.8 mg/kg or 1.6 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single doses of pantoprazole (oral and intravenous)
Number of subjects: 0
Study: 16650135

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 300 mg daily
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 300 mg daily
Number of subjects: 29
Study: 14675575

Group type: EXPERIMENTAL
Intervention: Beta VBT
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Gamma VBT
Number of subjects: 636

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 636
Study: 11016911

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 9001830

Group type: EXPERIMENTAL
Intervention: 400 mg suspension
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 400 mg capsule (laboratory batch)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 400 mg capsule (production batch)
Number of subjects: 3
Study: 1461795

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 6143969

Group type: EXPERIMENTAL
Intervention: BM 13.177
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31613883

Group type: EXPERIMENTAL
Intervention: Community treatment using ready-to-use therapeutic food
Number of subjects: 2869
Study: 29961295

Group type: EXPERIMENTAL
Intervention: Continuous plasma filtration group
Number of subjects: 86

Group type: COMPARATOR
Intervention: Routine treatment group
Number of subjects: 86
Study: 27331783

Group type: EXPERIMENTAL
Intervention: Low-cost high psychological fidelity simulation with debriefing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 20
Study: 24552977

Group type: EXPERIMENTAL
Intervention: Paroxetine 7.5 mg
Number of subjects: 1174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1174
Study: 20663779

Group type: EXPERIMENTAL
Intervention: Oral screen (OS) application
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (small‐dimensioned air‐permeable end cap (EC))
Number of subjects: 56
Study: 17978594

Group type: EXPERIMENTAL
Intervention: Nebivolol (2.5, 5, 10, 20, or 40 mg once daily)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Nebivolol (10 mg and higher)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 14534925

Group type: EXPERIMENTAL
Intervention: Combination of regular-release (RR) and sustained-release (SR) levodopa/benserazide
Number of subjects: 23
Study: 11069460

Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg daily for 48 weeks
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo for 48 weeks
Number of subjects: 212
Study: 9238408

Group type: EXPERIMENTAL
Intervention: ECG criteria (Casale/Devereux, Cornell product, Cornell voltage, 12‐lead voltage product, sum of the 12‐lead, Rautaharju, Sokolow‐Lyon, Romhilt‐Estes point score)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Echo‐LVM index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ECG measurements combined with non‐ECG characteristics
Number of subjects: 0
Study: 1595992

Group type: EXPERIMENTAL
Intervention: SK&F 104353 (800 micrograms inhaled)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (20 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6379136

Group type: EXPERIMENTAL
Intervention: Immediate administration of a three-dose course of intravenously administered indomethacin in addition to usual medical therapy (fluid restriction and use of diuretics or digitalis or both)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Usual medical therapy alone initially, with indomethacin as the first and surgery as the final backup measure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Usual medical therapy alone initially, with surgery alone as backup
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual medical therapy with surgery as backup
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin as part of initial treatment
Number of subjects: 0
Study: 30376652

Group type: EXPERIMENTAL
Intervention: CSBI (schoolMAX)
Number of subjects: 103

Group type: COMPARATOR
Intervention: SAU (services-as-usual)
Number of subjects: 103
Study: 28356648

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise and joint mobilization (Group II)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Therapeutic exercise only (Group I)
Number of subjects: 18
Study: 25760553

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (probiotic)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 23374677

Group type: EXPERIMENTAL
Intervention: Folic acid 0.5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Folic acid 2 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison with children from trial before fortification
Number of subjects: 20
Study: 21185401

Group type: EXPERIMENTAL
Intervention: CRT ON
Number of subjects: 508

Group type: COMPARATOR
Intervention: CRT OFF
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: CRT ON with reverse remodeling
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: CRT ON without reverse remodeling
Number of subjects: 508
Study: 19928739

Group type: EXPERIMENTAL
Intervention: Tuberous sclerosis patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 23
Study: 17244900

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infused intra‐articular at 4 mL/hour for 72 hours
Number of subjects: 63

Group type: COMPARATOR
Intervention: 0.9% saline infused intra‐articular at 4 mL/hour for 72 hours (placebo)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No intra‐articular infusion catheter (control)
Number of subjects: 63
Study: 16702565

Group type: EXPERIMENTAL
Intervention: Postural restriction (cervical collar and upright head position for 2 days)
Number of subjects: 119

Group type: COMPARATOR
Intervention: No postural restriction
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Postural restriction
Number of subjects: 119

Group type: COMPARATOR
Intervention: Postural restriction vs No postural restriction
Number of subjects: 119
Study: 10819474

Group type: EXPERIMENTAL
Intervention: Postoperative SIRS(+) patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Postoperative SIRS(+) patients with complications
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Postoperative SIRS(+) patients lasting 3 days or longer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SIRS(+) patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: SIRS(-) patients
Number of subjects: 40
Study: 8797186

Group type: COMPARATOR
Intervention: Nortriptyline (NT) 75 mg daily for up to 7 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nortriptyline (NT)
Number of subjects: 38